🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 23/12/2010 | 35,06 | 35,56 | 34,89 | 35,39 | +0,80% | 1,91% | 1.438.800 |
| 22/12/2010 | 35,84 | 35,98 | 34,89 | 35,11 | -3,33% | 3,04% | 2.455.400 |
| 21/12/2010 | 35,58 | 36,40 | 35,46 | 36,32 | +2,14% | 2,64% | 1.561.200 |
| 20/12/2010 | 35,75 | 35,83 | 35,20 | 35,56 | +0,31% | 1,76% | 1.367.900 |
| 17/12/2010 | 34,53 | 35,73 | 34,31 | 35,45 | +2,49% | 4,11% | 3.242.600 |
| 16/12/2010 | 34,31 | 34,82 | 34,18 | 34,59 | +0,61% | 1,87% | 948.700 |
| 15/12/2010 | 34,17 | 34,70 | 34,09 | 34,38 | +0,53% | 1,79% | 1.630.000 |
| 14/12/2010 | 34,04 | 34,35 | 33,98 | 34,20 | +0,74% | 1,09% | 984.500 |
| 13/12/2010 | 34,25 | 34,39 | 33,72 | 33,95 | -0,53% | 1,96% | 1.316.000 |
| 10/12/2010 | 33,30 | 34,54 | 33,28 | 34,13 | +2,89% | 3,78% | 2.595.600 |
| 09/12/2010 | 32,58 | 33,24 | 32,08 | 33,17 | +2,28% | 3,56% | 2.639.700 |
| 08/12/2010 | 33,15 | 33,44 | 32,28 | 32,43 | -1,99% | 3,50% | 1.933.200 |
| 07/12/2010 | 33,58 | 33,77 | 33,00 | 33,09 | -0,03% | 2,29% | 2.138.300 |
| 06/12/2010 | 33,40 | 33,58 | 33,02 | 33,10 | -1,16% | 1,68% | 1.717.700 |
| 03/12/2010 | 33,37 | 33,66 | 33,11 | 33,49 | +0,36% | 1,65% | 4.680.100 |
| 02/12/2010 | 33,40 | 33,54 | 33,15 | 33,37 | -0,27% | 1,17% | 1.805.500 |
| 01/12/2010 | 33,64 | 33,87 | 33,38 | 33,46 | +1,00% | 1,46% | 2.131.000 |
| 30/11/2010 | 33,41 | 33,62 | 33,03 | 33,13 | -2,18% | 1,77% | 2.156.100 |
| 29/11/2010 | 34,08 | 34,09 | 33,31 | 33,87 | -1,20% | 2,29% | 1.162.000 |
| 26/11/2010 | 33,65 | 34,37 | 33,56 | 34,28 | +1,30% | 2,41% | 502.400 |
| 24/11/2010 | 33,69 | 34,13 | 33,69 | 33,84 | +1,20% | 1,31% | 1.029.900 |
| 23/11/2010 | 34,00 | 34,00 | 33,10 | 33,44 | -2,48% | 2,65% | 1.928.800 |
| 22/11/2010 | 34,32 | 34,61 | 33,85 | 34,29 | +0,12% | 2,21% | 1.134.200 |
| 19/11/2010 | 34,78 | 34,78 | 34,16 | 34,25 | -1,92% | 1,78% | 1.652.200 |
| 18/11/2010 | 33,87 | 35,10 | 33,87 | 34,92 | +3,80% | 3,63% | 3.025.000 |
| 17/11/2010 | 33,97 | 34,03 | 33,40 | 33,64 | -1,35% | 1,85% | 1.711.400 |
| 16/11/2010 | 34,36 | 34,40 | 33,70 | 34,10 | -1,33% | 2,04% | 1.667.700 |
| 15/11/2010 | 33,98 | 34,67 | 33,95 | 34,56 | +2,34% | 2,12% | 2.100.900 |
| 12/11/2010 | 34,66 | 34,66 | 33,77 | 33,77 | -3,49% | 2,57% | 1.763.400 |
| 11/11/2010 | 34,20 | 34,99 | 33,89 | 34,99 | +1,60% | 3,22% | 1.978.200 |